Ultraviolet light, vitamin D and type 1 diabetes

Original article:
The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Mohr SB, Garland CF, Gorham ED, Garland FC. *Diabetologia* 2008; 51: 1391–8.

Summary and Comment:
Roger Bouillon, Leuven, Belgium
(roger.bouillon@med.kuleuven.ac.be)

Key words:
Vitamin D, ultraviolet light, incidence of type 1 diabetes, sun exposure, nutrition, epidemiology

Summary

Mohr et al. describe the first analysis of the relationship between ultraviolet B (UVB) exposure and age-standardized incidence rates of type 1 diabetes in children. The study comprised the authors' published data on UVB exposure worldwide (corrected for cloud cover) [1] and the Diabetes Mondiale (DiaMond) 2000 data on the incidence of type 1 diabetes in 51 regions of the world [2]. The authors observed a higher rate of type 1 diabetes in areas of the world with lower UVB exposure ($p < 0.05$ in multiple regression analysis) *(Fig. 1)*.

The authors observed a higher rate of type 1 diabetes in areas of the world with lower UVB exposure

As UVB light is the main source of skin-produced vitamin D (285–310 nm UVB light is essential for the photochemical conversion of 7-dehydrocholesterol into previtamin D3 and vitamin D3), the authors suggest that the link between UVB exposure and the incidence of type 1 diabetes is mediated by vitamin D.

Comment

This report makes three different observations in relation to the incidence rate of type 1 diabetes:
1. (negative association) latitude ($R^2 = 0.25$; $p < 0.0001$),
2. (negative association) UVB exposure ($R^2 = 0.30$; $p < 0.05$),
3. (positive association) *per capita* health expenditure ($R^2 = 0.42$; $p < 0.004$).

Using the parameters of UVB exposure and *per capita* health expenditure in a multiple regression analysis, the model could explain an impressive 42% of the variation in incidence rate of type 1 diabetes ($p < 0.0001$).

Using the parameters of UVB exposure and per capita health expenditure in a multiple regression analysis, the model could explain an impressive 42% of the variation in incidence rate of type 1 diabetes

But are these results such a surprise? The greater incidence of type 1 diabetes in countries at a higher latitude and the general north-south gradient have been repeatedly described. As UVB exposure and latitude are physically also strongly linked, it may be predicted that UVB and type 1 diabetes are also likely to be linked. The authors did not describe a model that included both latitude *and* UVB exposure in order to establish the most dominant factor. The association of health care expenditure (or *per capita* income) and type 1 diabetes is also well known and shows an even stronger link than latitude, yet no one believes it to be a causal link.

How likely is this impressive association between UVB and type 1 diabetes mediated by differences in vitamin D status? The answer depends on two additional questions:
1. How strong is the relationship between UVB exposure and vitamin D status?
2. How strong is the impact of vitamin D status on diabetes in general or on type 1 diabetes?

The correlation between the vitamin D status of different populations and their potential exposure to UVB is rather poor. Indeed, in European countries a positive relation between latitude and 25-hydroxyvitamin D status has repeatedly been found: the best 25-hydroxyvitamin D status is found in Scandinavia, in contrast to the Mediterranean countries, where the status is lower [3]. An overview of vitamin D status, as reported for healthy subjects in some 500 publications, revealed a mean 25-hydroxyvitamin D level worldwide of about 21 ng/ml, with surprisingly very little difference according to a tropical or northern climate [4]. Most likely, the skin pigmentation, clothing and sun-seeking behaviour (or lack of it) largely compensate for the different potential UVB exposure. More specifically, the high incidence of type 1 diabetes in Scandinavia is in sharp contrast to the low incidence in China, whereas it seems that vitamin D status in

Fig. 1: *Age-standardized incidence rates of type 1 diabetes per 100,000 boys <14 years of age, by latitude, in 51 regions worldwide in 2002 [3]. Data points are shown by dots. Where space allows, names shown adjacent to dots denote location (Lux, Luxembourg). Where space is limited, the following numerical codes designate the location: 2. Beja, Tunisia; 3. Gafsa, Tunisia; 4. Kairoan, Tunisia; 5. Monastir, Tunisia; 7. Mauritius; 8. Wuhan, China; 9. Sichuan, China; 10. Huhehot, China; 16. Nanjing, China; 17. Jinan, China; 21. Harbin, China; 23. Changsha, China; 25. Hainan, China; 29. Hong Kong, China; 31. Israel; 32. Chiba, Japan; 33. Hokkaido, Japan; 34. Okinawa, Japan; 36. Novosibirsk, Russia; 38. Antwerp, Belgium; 39. Varna, Bulgaria; 40. Denmark; 43. France; 44. Baden Baden, Germany; 45. Attica, Greece; 48. Sicily, Italy; 49. Pavia, Italy; 50. Marche, Italy; 52. Lazio, Italy; 59. Krakow, Poland; 61. Algarve, Portugal; 62. Coimbra, Portugal; 63. Madeira, Portugal; 64. Portalegre, Portugal; 65. Bucharest, Romania; 67. Slovakia; 68. Catalonia, Spain; 71. Leicestershire, UK; 72. Northern Ireland, UK; 77. Allegheny, PA, USA; 80. Avellaneda, Argentina; 82. Corrientes, Argentina; 87. Paraguay; 88. Lima, Peru; 90. Caracas, Venezuela; 97. Auckland, New Zealand. Data points not labelled because of space constrains (latitude in degrees, rate per 100,000): 11. Dalian, China (39, 1.1); 12. Guilin, China (24, 0.6); 13. Beijing, China (40, 0.6); 18. Jilin, China (43, 0.4); 19. Shenyang, China (42, 0.4); 20. Lanzhou, China (36, 0.5); 22. Nanning, China (23, 0.3); 24. Zhengzhou, China (35, 0.2); 26. Tie Ling, China (42, 0.2); 27. Zunyi, China (28, 0.1); 28. Wulumuqi, China (44, 0.9); 35. Karachi, Pakistan (25, 0.5); 37. Austria (48, 9.8); 46. Hungary (47, 8.7); 51. Turin, Italy (45, 11.9); 53. Lombardia, Italy (46, 7.6); 66. Slovenia (46, 6.8); 79. Chicago, IL, USA (42, 10.2).* $R^2 = 0.25$, $p < 0.001$.

the northern part of China is substantially lower than in Scandinavia. Another striking discordance is the very poor vitamin D status in many Muslim countries but very low incidence rates of type 1 diabetes [5]. Of course it may well be that UVB or vitamin D status is a modifying factor depending on the genetic background. Also the US National Health and Nutrition Examination Survey (NHANES) data on prevailing 25-hydroxyvitamin D levels [6] are only poorly related to UVB exposure. However, the lack of essential data on vitamin D status early in life (during pregnancy, in cord serum or during the first year of life) means that the association with later occurrence of type 1 diabetes has not been properly addressed.

How strong is the link between vitamin D status and diabetes? There is a strong association between (poor) vitamin D status (as revealed by serum 25-hydroxyvitamin D) and all aspects of the metabolic syndrome (obesity, type 2 diabetes, hypertension, cardiovascular risks and events) [5, 7]. With regard to vitamin D and autoimmune diseases, there are numerous data

Table I: *Vitamin D and type 1 diabetes: case-control studies in humans.*

Study	Parameter	Subjects	Odds ratio
EURODIAB [9]	Vitamin D supplementation during first year of life	<5 years 5–9 years 10–14 years	0.83 0.81 0.47
Stene et al. [10]	Vitamin D supplementation with 10 μg cod liver oil >5 times/week during first year of life	<15 years	0.74
Hypponen et al. [11]	Vitamin D supplementation of 2000 IU/day during first year of life	1–31 years	0.12
	Rickets during first year of life	1–31 years	2.60
Fronczak et al. [12]	Vitamin D via variable food intake during pregnancy	5 years	0.49
Tenconi et al. [13]	Vitamin D intake during lactation	14 years	0.31

that leave no doubt that 1,25-hydroxyvitamin D is a potent immune agent, activating the innate immune system. It also downregulates the acquired immune system by a coherent action on all cell types involved (antigen presenting cells, all T cells, B cells and some natural killer cells), as well as by direct regulation of gene transcription of at least 10 different key genes involved in the immune response (e.g. interleukin [IL]-1, IL-2, IL-4, IL-12, interferon-γ).

Vitamin D supplementation early in life can reduce the subsequent risk of type 1 diabetes by about 30% according to a critical analysis of five retrospective studies

In animal models, 1,25-hydroxyvitamin D or its analogues has been shown to have potent preventive effects on several models of autoimmune diseases, including type 1 diabetes in the non-obese diabetic (NOD) mouse. In humans, polymorphisms in the 1α-hydroxylase gene are associated with the risk of type 1 diabetes [8]. Vitamin D supplementation early in life can reduce the subsequent risk of type 1 diabetes by about 30% according to a critical analysis of five retrospective studies *(Table I)* [9–13]. Unfortunately, these are not well-documented studies with regard to vitamin D dosage and compliance and none have reported 25-hydroxyvitamin D levels early in life (in contrast to the Mohr paper). In addition, two well-controlled independent studies in NOD mice showed that vitamin D deficiency early in life enhances the risk of later diabetes [14, 15]. These 'reverse engineering' studies are a strong argument for causality (not discussed in the Mohr paper).

Finally, Mohr et al. argue for active interventions to bring 25-hydroxyvitamin D levels into the 50–60 ng/ml (125–150 nmol/l) range through either higher sun exposure or vitamin doses higher than the upper limit currently set by US and EU authorities. However, this is premature given that vitamin D supplementation, beyond what is known to be needed for normal calcium and bone homeostasis, has yet to be proven safe and efficient for non-calcemic endpoints such as the immune system (including type 1 diabetes), cancer and cardiovascular or metabolic risk factors.

Mohr et al. describe a strong association between latitude or UVB exposure and incidence of type 1 diabetes around the world. They also confirm strong links between vitamin D status and diabetes, especially type 1 diabetes, based on molecular, genetic, cellular and preclinical studies as well as on association studies in children and adults. The causal link between UVB exposure, vitamin D status and type 1 diabetes, however, still needs to be formally proven by randomized controlled trials.

These and other data have generated a strong hypothesis that is in need of good clinical prospective trials to guide future clinical practice.

References

1. Mohr SB, Garland CF, Gorham ED et al. Is ultraviolet B irradiance inversely associated with incidence rates of endometrial cancer: an ecological study of 107 countries. *Prev Med* 2007; 45: 327–31.
2. Karvonen M, Viik-Kajander M, Moltchanova E et al.; Diabetes Mondiale (DiaMond) Project Group. Incidence of childhood type 1 diabetes worldwide. *Diabetes Care* 2000; 23: 1516–26.
3. van der Wielen RP, Lowik MR, van den BH et al. Serum vitamin D concentrations among elderly people in Europe. *Lancet* 1995; 346: 207–10.

4. Hagenau T, Vest R, Gissel TN et al. Global vitamin D levels in relation to age, gender, skin pigmentation and latitude: an ecologic meta-regression analysis. *Osteoporos Int* 2009; 20: 133–40.
5. Bouillon R, Carmeliet G, Verlinden L et al. Vitamin D and human health: lessons from vitamin D receptor null mice. *Endocr Rev* 2008; 29: 726–76.
6. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. *Arch Intern Med* 2009; 169: 626–32.
7. Bouillon R. Vitamin D as potential baseline therapy for blood pressure control. *Am J Hypertens* 2009; 22: 816.
8. Bailey R, Cooper JD, Zeitels L et al. Association of the vitamin D metabolism gene CYP27B1 with type 1 diabetes. *Diabetes* 2007; 56: 2616–21.
9. The EURODIAB Substudy 2 Study Group. Vitamin D supplement in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. *Diabetologia* 1999; 42: 51–4.
10. Stene LC, Joner G; Norwegian Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. *Am J Clin Nutr* 2003; 78: 1128–34.
11. Hypponen E, Laara E, Reunanen A et al. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. *Lancet* 2001; 358: 1500–3.
12. Fronczak CM, Baron AE, Chase HP et al. In utero dietary exposures and risk of islet autoimmunity in children. *Diabetes Care* 2003; 26: 3237–42.
13. Tenconi MT, Devoti G, Comelli M et al. Major childhood infectious diseases and other determinants associated with type 1 diabetes: a case-control study. *Acta Diabetol* 2007; 44: 14–19.
14. Giulietti A, Gysemans C, Stoffels K et al. Vitamin D deficiency in early life accelerates Type 1 diabetes in non-obese diabetic mice. *Diabetologia* 2004; 47: 451–62.
15. Zella JB, DeLuca HF. Vitamin D and autoimmune diabetes. *J Cell Biochem* 2003; 88: 216–22.